Osborne Partners Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.9M Sell
41,743
-2,223
-5% -$1.07M 1.16% 22
2026
Q1
$21.6M Buy
43,966
+8,793
+25% +$4.77M 1.14% 24
2025
Q4
$20.4M Buy
35,173
+2,565
+8% +$1.45M 1.05% 23
2025
Q3
$15.8M Buy
32,608
+635
+2% +$296K 0.8% 36
2025
Q2
$13M Buy
31,973
+3,199
+11% +$1.34M 0.69% 49
2025
Q1
$14.3M Sell
28,774
-476
-2% -$258K 0.83% 36
2024
Q4
$15.2M Buy
29,250
+697
+2% +$383K 0.88% 30
2024
Q3
$17.7M Sell
28,553
-321
-1% -$190K 1% 25
2024
Q2
$16M Buy
28,874
+8
+0% +$4.58K 0.96% 29
2024
Q1
$16.8M Buy
28,866
+527
+2% +$296K 1.03% 26
2023
Q4
$15M Buy
28,339
+849
+3% +$411K 0.98% 28
2023
Q3
$13.9M Buy
27,490
+292
+1% +$156K 1.03% 28
2023
Q2
$14.2M Buy
27,198
+643
+2% +$347K 1.02% 26
2023
Q1
$15.3M Buy
26,555
+209
+0.8% +$118K 1.12% 24
2022
Q4
$14.5M Buy
26,346
+273
+1% +$145K 1.14% 23
2022
Q3
$13.2M Buy
26,073
+389
+2% +$218K 1.11% 23
2022
Q2
$14M Sell
25,684
-892
-3% -$491K 1.07% 23
2022
Q1
$15.7M Buy
26,576
+776
+3% +$446K 1.16% 25
2021
Q4
$17.2M Sell
25,800
-26
-0.1% -$16.2K 1.26% 21
2021
Q3
$14.8M Buy
25,826
+87
+0.3% +$47.8K 1.19% 23
2021
Q2
$13M Buy
25,739
+479
+2% +$226K 1.07% 23
2021
Q1
$11.5M Buy
25,260
+516
+2% +$246K 1.05% 25
2020
Q4
$11.5M Sell
24,744
-7,768
-24% -$3.64M 1.41% 15
2020
Q3
$14.4M Sell
32,512
-1,083
-3% -$447K 2.89% 3
2020
Q2
$12.2M Sell
33,595
-1,130
-3% -$379K 2.61% 5
2020
Q1
$9.85M Buy
34,725
+566
+2% +$178K 2.56% 8
2019
Q4
$11.1M Sell
34,159
-3,133
-8% -$950K 2.25% 8
2019
Q3
$10.9M Sell
37,292
-712
-2% -$204K 2.18% 10
2019
Q2
$11.2M Sell
38,004
-628
-2% -$173K 2.14% 7
2019
Q1
$10.6M Sell
38,632
-840
-2% -$209K 2.06% 9
2018
Q4
$8.83M Sell
39,472
-447
-1% -$105K 1.32% 19
2018
Q3
$9.74M Sell
39,919
-13,708
-26% -$3.15M 1.25% 21
2018
Q2
$11.1M Sell
53,627
-4,307
-7% -$914K 1.51% 12
2018
Q1
$12M Sell
57,934
-154
-0.3% -$32.3K 1.65% 12
2017
Q4
$11M Sell
58,088
-2,548
-4% -$488K 1.46% 15
2017
Q3
$11.5M Sell
60,636
-1,330
-2% -$241K 1.57% 13
2017
Q2
$10.8M Buy
61,966
+1,299
+2% +$218K 1.54% 15
2017
Q1
$9.32M Sell
60,667
-910
-1% -$139K 1.33% 19
2016
Q4
$8.69M Sell
61,577
-705
-1% -$104K 1.27% 18
2016
Q3
$9.91M Sell
62,282
-1,652
-3% -$255K 1.48% 18
2016
Q2
$9.45M Sell
63,934
-4,470
-7% -$660K 1.41% 18
2016
Q1
$9.69M Sell
68,404
-335
-0.5% -$44.9K 1.42% 17
2015
Q4
$9.75M Sell
68,739
-1,380
-2% -$184K 1.42% 19
2015
Q3
$8.57M Buy
70,119
+691
+1% +$90K 1.26% 27
2015
Q2
$9.01M Sell
69,428
-1,215
-2% -$158K 1.21% 27
2015
Q1
$9.49M Sell
70,643
-7,725
-10% -$996K 1.25% 26
2014
Q4
$9.82M Buy
78,368
+1,570
+2% +$191K 1.19% 30
2014
Q3
$9.35M Sell
76,798
-450
-0.6% -$54.7K 1.21% 29
2014
Q2
$9.12M Buy
77,248
+804
+1% +$94.6K 1.17% 29
2014
Q1
$9.19M Buy
76,444
+68
+0.1% +$8.09K 1.2% 30
2013
Q4
$8.5M Sell
76,376
-599
-0.8% -$59.6K 1.11% 34
2013
Q3
$7.09M Sell
76,975
-805
-1% -$72.8K 0.99% 40
2013
Q2
$6.58M Buy
+77,780
New +$6.47M 0.94% 41

Other funds holding TMO

Osborne Partners Capital Management's TMO Position: Q2 2026 in Review

Osborne Partners Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 5.1% in Q2 2026, selling an estimated $1.07M and leaving 41,743 shares worth $20.9M. The position accounts for 1.16% of the portfolio, ranked #22.

Osborne Partners Capital Management first reported a position in TMO in Q2 2013 and has held it in 53 quarters since. The position peaked at $21.6M in Q1 2026. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Osborne Partners Capital Management held 41,743 shares of Thermo Fisher Scientific worth $20.9M as of Q2 2026.
  • Osborne Partners Capital Management sold 2,223 Thermo Fisher Scientific shares in Q2 2026, an estimated $1.07M.
  • Thermo Fisher Scientific made up 1.16% of Osborne Partners Capital Management's portfolio in Q2 2026, its #22 holding.
  • Osborne Partners Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 53 quarters since.
  • Osborne Partners Capital Management's Thermo Fisher Scientific position peaked at $21.6M in Q1 2026.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Osborne Partners Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.